We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

57 hedge funds and large institutions have $55.8M invested in NeuBase Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 16 increasing their positions, 4 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 4

200% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 11

79% more capital invested

Capital invested by funds: $31.1M → $55.8M (+$24.7M)

63% more funds holding

Funds holding: 35 → 57 (+22)

37% less call options, than puts

Call options by funds: $4.99M | Put options by funds: $7.9M

Holders
57
Holders Change
+22
Holders Change %
+62.86%
% of All Funds
1.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
16
Reduced
4
Closed
11
Calls
$4.99M
Puts
$7.9M
Net Calls
-$2.92M
Net Calls Change
-$2.85M

Top Buyers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
+$10.4M
2
BFA
BlackRock Fund Advisors
California
+$4.87M
3
VM
VHCP Management
New York
+$4.49M
4
LOAMU
Lombard Odier Asset Management (USA)
New York
+$2.82M
5
BIT
BlackRock Institutional Trust
California
+$1.75M

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$2.23M
2
BIM
Bogle Investment Management
Massachusetts
-$880K
3
SH
Scepter Holdings
Texas
-$785K
4
CS
Credit Suisse
Switzerland
-$663K
5
GC
Gratia Capital
California
-$658K
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
26
Metropolitan Life Insurance Company (MetLife)
New York
$245K +$241K +64 New
PPCM
27
Pillar Pacific Capital Management
California
$175K – – –
NFA
28
Nationwide Fund Advisors
Ohio
$151K +$151K +40 New
RhumbLine Advisers
29
RhumbLine Advisers
Massachusetts
$140K +$139K +37 New
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$135K +$30.1K +8 +29%
AIG
31
American International Group
New York
$131K +$128K +34 New
Morgan Stanley
32
Morgan Stanley
New York
$129K +$11.3K +3 +10%
AQR Capital Management
33
AQR Capital Management
Connecticut
$125K – – –
VKH
34
Virtu KCG Holdings
New York
$120K -$3.77K -1 -3%
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$117K -$407K -108 -78%
Citadel Advisors
36
Citadel Advisors
Florida
$106K +$105K +28 New
Wells Fargo
37
Wells Fargo
California
$104K +$33.9K +9 +50%
BA
38
BlackRock Advisors
Delaware
$101K +$102K +27 New
ProShare Advisors
39
ProShare Advisors
Maryland
$97K +$97.9K +26 New
AllianceBernstein
40
AllianceBernstein
Tennessee
$96K +$94.1K +25 New
SO
41
STRS Ohio
Ohio
$68K +$67.8K +18 New
HF
42
Hoxton Financial
West Virginia
$47K +$15.1K +4 +50%
NES
43
New England Securities
New York
$38K +$37.6K +10 New
FNBT
44
FineMark National Bank & Trust
Florida
$37K – – –
Bank of America
45
Bank of America
North Carolina
$35K +$22.6K +6 +200%
SGAM
46
Smith Group Asset Management
Texas
$32K +$30.1K +8 New
ST
47
Spot Trading
Illinois
$28K +$26.4K +7 New
TRCT
48
Tower Research Capital (TRC)
New York
$23K +$18.8K +5 +500%
HCC
49
Hirtle Callaghan & Co
Pennsylvania
$21K – – –
Deutsche Bank
50
Deutsche Bank
Germany
$19K -$22.6K -6 -55%
1
2
3

NBSE Hedge Fund Activity: Q2 2014 in Review

57 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2014, worth a combined $55.8M — up 79% from $31.1M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new NBSE positions and 11 closed out — a net gain of 22 holders — while 16 added to existing stakes and 4 trimmed.

The largest buyer was Visium Asset Management, opening a new position worth an estimated $10.4M. The largest seller was EAM Investors, exiting entirely with an estimated $2.23M sold.

  • 57 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2014, up from 35 in Q1 2014.
  • Funds reported $55.8M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2014, up 79% quarter-over-quarter.
  • 33 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2014 and 11 closed out, a net change of +22 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2014 was Visium Asset Management, an estimated $10.4M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2014 was EAM Investors, an estimated $2.23M sold.

Based on aggregated 13F filings for Q2 2014.